文献速递膀胱癌与上尿路尿路上皮癌

游离DNA甲基化作为SWOG S1314中肌层浸润性膀胱癌患者新辅助化疗反应预测生物标志物

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
PubMed 文献 · Eur Urol Oncol · 2023-04-20

SWOG S1314是一项前瞻性协作组试验,纳入72例肌层浸润性膀胱癌患者,在新辅助化疗前及化疗期间采集血浆,用甲基化芯片检测游离DNA甲基化。基于化疗前血浆开发的甲基化反应评分可预测病理反应,联合循环膀胱DNA分数在基线及第一周期后预测79%患者的病理反应。研究为探索性分析,样本量有限。

要点

  • 基于化疗前血浆cfDNA甲基化构建的mR-score可预测肌层浸润性膀胱癌新辅助化疗的病理反应。
  • 第一周期新辅助化疗后采集的血浆mR-score预测能力与化疗前相似。
  • 联合mR-score与循环膀胱DNA分数的模型在基线及第一周期后正确预测79%患者的病理反应。

核心结论

  • 本研究提供概念验证,证明cfDNA甲基化可用于构建膀胱癌患者新辅助化疗反应的分类器。

研究设计与样本

  • SWOG S1314是一项前瞻性协作组试验,纳入肌层浸润性膀胱癌患者(cT2-T4aN0M0,存活肿瘤≥5 mm),主要目的为评估COXEN基因表达特征对新辅助化疗反应的预测价值(反应定义为根治性膀胱切除术后pT0N0或≤pT1N0)。
  • 本探索性分析前瞻性采集72例患者的化疗前及化疗期间血样,使用Infinium MethylationEPIC BeadChip阵列检测血浆cfDNA甲基化。
  • 除血浆采集外无额外干预;采用随机森林机器学习算法构建治疗反应预测分类器。

主要发现

  • 使用化疗前血浆cfDNA开发了预测病理反应的甲基化反应评分(mR-score)。
  • 第一周期新辅助化疗后采集的血浆样本所得mR-score预测能力相似。
  • 利用cfDNA甲基化数据计算循环膀胱DNA分数,对治疗反应具有适度但独立的预测能力。
  • 联合mR-score与循环膀胱DNA分数的模型,基于基线和第一周期化疗后血浆,正确预测79%患者的病理反应。

局限性

  • 样本量有限。
  • 循环膀胱DNA水平相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard of care in muscle-invasive bladder cancer (MIBC). However, treatment is intense, and the overall benefit is small, necessitating effective biomarkers to identify patients who will benefit most. OBJECTIVE: To characterize cell-free DNA (cfDNA) methylation in patients receiving NAC in SWOG S1314, a prospective cooperative group trial, and to correlate the methylation signatures with pathologic response at radical cystectomy. DESIGN, SETTING, AND PARTICIPANTS: SWOG S1314 is a prospective cooperative group trial for patients with MIBC (cT2-T4aN0M0, ≥5 mm of viable tumor), with a primary objective of evaluating the coexpression extrapolation (COXEN) gene expression signature as a predictor of NAC response, defined as achieving pT0N0 or ≤pT1N0 at radical cystectomy. For the current exploratory analysis, blood samples were collected prospectively from 72 patients in S1314 before and during NAC, and plasma cfDNA methylation was measured using the Infinium MethylationEPIC BeadChip array. INTERVENTION: No additional interventions besides plasma collection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Differential methylation between pathologic responders (≤pT1N0) and nonresponders was analyzed, and a classifier predictive of treatment response was generated using the Random Forest machine learning algorithm. RESULTS AND LIMITATIONS: Using prechemotherapy plasma cfDNA, we developed a methylation-based response score (mR-score) predictive of pathologic response. Plasma samples collected after the first cycle of NAC yielded mR-scores with similar predictive ability. Furthermore, we used cfDNA methylation data to calculate the circulating bladder DNA fraction, which had a modest but independent predictive ability for treatment response. In a model combining mR-score and circulating bladder DNA fraction, we correctly predicted pathologic response in 79% of patients based on their plasma collected at baseline and after one cycle of chemotherapy. Limitations of this study included a limited sample size and relatively low circulating bladder DNA levels. CONCLUSIONS: Our study provides the proof of concept that cfDNA methylation can be used to generate classifiers of NAC response in bladder cancer patients. PATIENT SUMMARY: In this exploratory analysis of S1314, we demonstrated that cell-free DNA methylation can be profiled to generate biomarker signatures associated with neoadjuvant chemotherapy response. With validation in additional cohorts, this minimally invasive approach may be used to predict chemotherapy response in locally advanced bladder cancer and perhaps also in metastatic disease.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lu YT, Plets M, Morrison G, et al. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023. PMID: 37087309. doi:10.1016/j.euo.2023.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。